SS-31 won FDA approval for Barth syndrome; its myopathy Phase 3 missed

What is SS-31, and how does it work?

SS-31 is a small synthetic tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that concentrates in the inner mitochondrial membrane and binds cardiolipin, a phospholipid unique to that membrane.

Alternating cationic and aromatic residues drive that selective concentration. Once bound to cardiolipin, SS-31 appears to stabilize the geometry of cristae and the respiratory supercomplexes assembled along them.

In diseased or oxidatively stressed mitochondria, cardiolipin is prone to peroxidation and complex disassembly, which increases electron leak and reactive oxygen species output while degrading ATP synthesis efficiency. Stabilizing that structure is the proposed route to lower ROS and better energy output.

The SS-31 mechanism is well worked out at the level of isolated mitochondria and animal models. It is one of the more mechanistically specific stories in the research-peptide space, and it is the reason SS-31 attracted a serious clinical trial program rather than staying a forum curiosity. For another mitochondrial peptide, see the MOTS-c human evidence.

Why doesn't SS-31's mechanism guarantee a clinical benefit?

SS-31 can reliably do what it is designed to do at the membrane and still fail to move a clinical endpoint, because mechanism and outcome are different tiers of evidence.

A clinical endpoint depends on dose reaching the right tissue at the right concentration, and on how much of the underlying pathology cardiolipin dysfunction drives in that specific disease. It also depends on whether the trial's chosen measure, such as a walk test or a volume on cardiac MRI, is sensitive enough to detect the effect size the drug can produce.

Keeping "the binding is real" separate from "the trial endpoint moved" is the single most important distinction in the SS-31 record.

Does SS-31 help heart failure?

SS-31 reduced heart volumes after a single IV infusion in a 36-patient trial, but daily subcutaneous dosing failed in a 71-patient Phase 2 trial ^[1]⁠^[4].

The positive trial was a small randomized, placebo-controlled study that gave a single 4-hour high-dose IV infusion of elamipretide to 36 patients with heart failure with reduced ejection fraction. It found significant reductions in left ventricular end-diastolic volume (18 mL, p=0.009) and end-systolic volume (14 mL, p=0.005), with no serious adverse events ^[1]. That is a statistically clean result, but from a single infusion, a surrogate imaging endpoint, and 36 people, not a demonstration that daily subcutaneous dosing improves how patients feel or function.

In the 71-person PROGRESS-HF Phase 2 trial, elamipretide at 4 mg or 40 mg per day subcutaneously for 28 days did not significantly improve left ventricular end-systolic volume by cardiac MRI at either dose (p=0.90 and p=0.28) ^[4]. Same mechanism, same broad disease category, different route and duration, and the effect did not hold.

Critics cite PROGRESS-HF as proof that SS-31 does not work. It shows instead that a single IV bolus and a month of subcutaneous dosing are different exposures, without showing which variable mattered.

Does SS-31 help primary mitochondrial myopathy?

SS-31 improved walking distance in the small MMPOWER trial, but the 218-patient Phase 3 MMPOWER-3 trial missed both primary endpoints ^[2]⁠^[5].

The Phase I/II MMPOWER trial in 36 genetically confirmed primary mitochondrial myopathy patients found a dose-dependent improvement in six-minute walk distance (p=0.014). The highest-dose group improved 51.2 m versus 3.0 m for placebo at day 5 in the covariate-adjusted model (p=0.0297) ^[2]. That was a real, dose-responsive, statistically significant early signal.

MMPOWER-3 used 40 mg/day subcutaneously for 24 weeks and failed both primary endpoints: six-minute walk distance changed by -3.2 m versus placebo (p=0.69), and a fatigue score changed by -0.07 (p=0.37) ^[5]. A promising small-trial dose-response signal did not replicate at scale over a longer duration.

The MMPOWER-3 result is a real miss, not a matter of interpretation. Anyone citing MMPOWER without also citing MMPOWER-3 is giving a selectively edited version of the record.

Does SS-31 help Barth syndrome?

SS-31 missed its primary endpoints in a 12-week blinded phase in Barth syndrome, then showed walk-distance and symptom gains after 36 weeks of open-label use ^[3].

In the 12-person Phase 2/3 trial, the 12-week blinded crossover phase did not meet its primary endpoints on walk distance or symptom score ^[3]. In the open-label extension, 36 weeks of continued elamipretide produced a 95.9 m improvement in six-minute walk distance (p=0.024) and a 2.1-point improvement in symptom score (p=0.031) ^[3].

The trial is small, and the open-label phase lacks a concurrent placebo arm, so regression to the mean or practice effects cannot be fully excluded. It is still a legitimate signal that duration of exposure, not just dose, may matter for SS-31's clinical effect in cardiolipin-related mitochondrial disease.

Is SS-31 safe?

SS-31 was well tolerated across all five cited trials, including the 218-person MMPOWER-3 Phase 3, with injection-site reactions the most common issue ^[5].

That consistency counts for something, but it does not resolve the efficacy question. The tolerability record is also time-limited, and long-term data outside diseased trial populations do not exist.

Is SS-31 FDA approved?

Yes, narrowly: the FDA granted accelerated approval to Forzinity, an elamipretide (SS-31) formulation, for a specific Barth syndrome indication in September 2025. See the FDA announcement.

SS-31 also carries an FDA orphan designation history tied to Barth syndrome. Approval for one Barth syndrome indication and "has been studied for" heart failure or myopathy are not the same claim.

The Barth indication does not establish a longevity benefit or validate a multi-compound stack. It also does not make a separately supplied research formulation equivalent to the approved medicine. Stacks are covered in the mitochondrial peptide stack analysis.

How is SS-31 dosed in clinical trials?

SS-31 trials used subcutaneous injection at 4 to 40 mg once daily, or a single 4-hour IV infusion at 0.25 mg/kg/h in the earliest cardiac trial ^[1].

No oral human trial data exist, and oral bioavailability for a peptide this size is essentially nil.

What is still unknown about SS-31?

Three gaps matter more than any single SS-31 trial result:

• Dose and duration. Dose-response and duration in humans are unresolved. An early myopathy signal at high dose did not hold at Phase 3 scale ^[2]⁠^[5], while a Barth syndrome signal appeared only after 36 weeks, not 12 ^[3]. Nobody has run the trial that would isolate whether longer exposure, a different dose, or a different population is the fix.
• Healthy adults. Every cited trial population had a defined mitochondrial or cardiac disease, and none of the cited trials provides randomized data in healthy adults. Claims about general energy, exercise capacity, or longevity in a self-directed user are extrapolation from disease-population trials, and that is the biggest unstated leap in most forum protocols.
• Long-term safety. Safety beyond trial durations of weeks to months, and outside the Barth population, has not been established.

For longevity claims in general, see the lifespan evidence behind popular longevity peptides.